Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAKIP-AML: NK Cells + Talazoparib in AML
NCT05319249Phase 2Not yet recruiting
- Sponsor
- German Cancer Research Center
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells, Small Molecules
01
Overview
A Phase 2 trial of talazoparib, NK cell therapy (Anhui Provincial Hospital) in acute myeloid leukemia (AML), sponsored by German Cancer Research Center. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
talazoparibNK cell therapy (Anhui Provincial Hospital)
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05319249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319249.